

Durable Medical Equipment, Orthotics, Medical Supplies, and Repairs/Replacements (for Kentucky Only)

Policy Number: CS032KY.08
Effective Date: May 1, 2026

[➔ Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	2
Medical Records Documentation Used for Reviews	3
Definitions	3
Applicable Codes	3
Benefit Considerations	3
Clinical Evidence	4
References	11
Policy History/Revision Information	13
Instructions for Use	14

Related Policies

- [Airway Clearance Devices \(for Kentucky Only\)](#)
- [Beds and Mattresses \(for Kentucky Only\)](#)
- [Cochlear Implants \(for Kentucky Only\)](#)
- [Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes \(for Kentucky Only\)](#)
- [Electrical and Ultrasonic Bone Growth Stimulators \(for Kentucky Only\)](#)
- [Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation \(for Kentucky Only\)](#)
- [Enteral Nutrition \(Oral and Tube Feeding\) \(for Kentucky Only\)](#)
- [Hearing Instruments and Devices Including Wearable, Bone-Anchored, and Semi-Implantable \(for Kentucky Only\)](#)
- [Home Traction Therapy \(for Kentucky Only\)](#)
- [Lower Extremity Prosthetics \(for Kentucky Only\)](#)
- [Mechanical Stretching Devices \(for Kentucky Only\)](#)
- [Motorized Spinal Traction \(for Kentucky Only\)](#)
- [Obstructive and Central Sleep Apnea Treatment \(for Kentucky Only\)](#)
- [Omnibus Codes \(for Kentucky Only\)](#)
- [Pediatric Gait Trainers and Standing Systems \(for Kentucky Only\)](#)
- [Plagiocephaly and Craniosynostosis Treatment \(for Kentucky Only\)](#)
- [Pneumatic Compression Devices \(for Kentucky Only\)](#)
- [Sleep Studies \(for Kentucky Only\)](#)
- [Supply Policy, Professional](#)
- [Upper Extremity Prosthetic Devices \(for Kentucky Only\)](#)

Application

This Medical Policy only applies to the state of Kentucky.

This Medical Policy does not apply to Durable Medical Equipment or supplies used in an outpatient or inpatient facility.

When determining medical necessity, clinical guidelines will be applied in the following order:

1. Federal, state, and contractual requirements
2. InterQual® CP: Durable Medical Equipment
3. UnitedHealthcare Community Plan Medical Policy
4. InterQual® Medicare: Post Acute & Durable Medical Equipment
5. Centers for Medicare & Medicaid Services (CMS) DME Medicare Administrative Contractor (MAC)

For Durable Medical Equipment (DME), orthotics, Medical Supplies, and repairs/replacements, refer to the [Kentucky Administrative Regulations \(KAR\), Title 907, Chapter 001, Regulation 479: Medical supplies, equipment, and appliances covered benefits and reimbursement](#) for coverage criteria.

Contact Lenses & Scleral Bandages (Shells)

Contact lenses or scleral shells that are used to treat an injury or disease (e.g., corneal abrasion, keratoconus, or severe dry eye) are not considered DME and may be covered under the [Kentucky Administrative Regulations \(KAR\), Title 907, Chapter 001, Regulation 632: Vision program coverage provisions and requirements](#).

Repair and Replacement

For DME repair and replacement, refer to the [Kentucky Administrative Regulations \(KAR\), Title 907, Chapter 001, Regulation 479: Medical supplies, equipment, and appliances covered benefits and reimbursement](#) for coverage criteria.

Home Mechanical Ventilators and Respiratory Assist Devices (Applies for 2 Years of Age or Older)

For medical necessity clinical coverage criteria for mechanical ventilators, refer to the InterQual® CP: Durable Medical Equipment Home Mechanical Ventilation Devices: Invasive, Noninvasive, and Multifunction. If medical necessity cannot be determined using these criteria, refer to the InterQual® Client Defined, CP: Durable Medical Equipment Home Mechanical Ventilation Devices: Invasive, Noninvasive, and Multifunction (Custom) – UHG.

[Click here to view the InterQual® criteria.](#)

Home mechanical ventilators are not medically necessary for individuals with stable COPD, with an arterial PaCO₂ of less than 52 mm Hg while awake on room air.

Bilevel PAP devices (HCPCS codes E0470 and E0471) are considered medically necessary in certain clinical scenarios. For medical necessity clinical coverage criteria, refer to the InterQual® CP: Durable Medical Equipment, Noninvasive Airway Assistive Devices.

[Click here to view the InterQual® criteria.](#)

Due to insufficient evidence of safety and efficacy, bilevel PAP, with or without backup rate, is considered unproven and not medically necessary for individuals with central sleep apnea and obstructive sleep apnea when adherent use of bilevel PAP is for less than 4 hours during sleep time on at least 21 to 30 consecutive 24-hour periods.

Due to insufficient evidence of safety and efficacy, bilevel PAP is unproven and not medically necessary for individuals with COPD, with an arterial PaCO₂ of less than 52 mm Hg while awake on room air (even when the asleep PaCO₂ is at 55 mm Hg or more for at least 10 minutes or asleep PaCO₂ increase of > 10 mm Hg from baseline awake and > 50 mm Hg for at least 10 minutes during sleep time).

Dedicated Speech Generating Devices and Tracheo-Esophageal Voice Devices

For medical necessity clinical coverage criteria, refer to [Kentucky Administrative Regulations \(KAR\); Title 907, Chapter 001, Regulation 479: Durable medical equipment covered benefits and reimbursement](#).

Coverage Limitations and Exclusions

Refer to the [Kentucky Administrative Regulations \(KAR\), Title 907, Chapter 001, Regulation 479: Medical supplies, equipment, and appliances covered benefits and reimbursement](#) for coverage limitations and exclusions.

Medical Records Documentation Used for Reviews

Benefit coverage for health services is determined by the federal, state, or contractual requirements, and applicable laws that may require coverage for a specific service. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the services requested.

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures. Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request.

Definitions

Check the federal, state, or contractual definitions that supersede the definitions below.

Durable Medical Equipment (DME): Medical Equipment that is all of the following:

- Withstands repeated use;
- Is primarily and customarily used to serve a medical purpose;
- Is generally not useful to a person in the absence of an illness or injury; and
- Is appropriate for use in the home.

(907 KAR 1:479)

Medical Supplies: Items that are:

- Consumable;
- Nonreusable;
- Disposable; and
- Primarily and customarily used to serve a medical purpose.

(907 KAR 1:479)

Applicable Codes

UnitedHealthcare has adopted the requirements and intent of the National Correct Coding Initiative. The Centers for Medicare & Medicaid Services (CMS) has contracted with Palmetto to manage Pricing, Data Analysis and Coding (PDAC) for Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS). This notice is to confirm UnitedHealthcare has established the PDAC as a source for correct coding and coding clarification.

Benefit Considerations

Cranial Remolding Orthosis

Cranial molding helmets (cranial remolding orthosis, billed with HCPCS code S1040) are covered when they meet medical criteria. For all indications, refer to the Medical Policy titled [Plagiocephaly and Craniosynostosis Treatment \(for Kentucky Only\)](#).

Note: A protective helmet (HCPCS codes A8000-A8004) is not a cranial remolding device. It is considered a safety device worn to prevent injury to the head rather than a device needed for active treatment.

Enteral Pumps

Enteral pumps are covered as DME. Refer to the Medical Policy titled [Enteral Nutrition \(Oral and Tube Feeding\) \(for Kentucky Only\)](#) for information regarding formula.

Equipment Upgrades

- A change in the member's medical condition and equipment needs requires the same documentation as a new request.

- Equipment upgrades are equivalent to a new service.

Implanted Devices

Any device, appliance, pump, machine, stimulator, or monitor that is fully implanted into the body is not covered as DME. (If covered, the device is covered as part of the surgical service.)

Cochlear Implant Benefit Clarification: The external components (i.e., speech processor, microphone, and transmitter coil) are considered under the DME benefit, and the implantable components are considered under the medical-surgical benefit.

Insulin Pumps

Insulin pumps, disposable and durable, are covered. For state specific information on mandated coverage of diabetes supplies, refer to the federal, state, or contractual requirements. Refer to the Medical Policy titled [Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes \(for Kentucky Only\)](#).

Lymphedema Stockings for the Arm

Post-mastectomy lymphedema stockings for the arm are considered DME. For state specific information on mandated coverage, refer to the state or contractual requirements.

Clinical Evidence

Home Mechanical Ventilators

Home Mechanical Ventilators for Individuals With Chronic Obstructive Pulmonary Disease

Due to insufficient evidence, home mechanical ventilators (HMVs) are considered unproven for individuals with chronic stable chronic obstructive pulmonary disease (COPD) when arterial carbon dioxide pressure (PaCO₂) is less than 52 mm Hg while awake on room air.

Wu et al. (2022) conducted a systematic review and meta-analysis of 19 randomized controlled trials (RCTs) that involved 1,482 individuals to assess the effectiveness of long-term home noninvasive positive pressure ventilation (LTHNIPPV) in individuals with stable hypercapnic COPD. The study found that LTHNIPPV significantly reduced all-cause mortality compared with control treatments, with a relative risk (RR) of 0.76 (95% CI, 0.61-0.95; p = 0.02). It also lowered hospital admission rates, improved arterial oxygen pressure (PaO₂), reduced PaCO₂, and enhanced exercise capacity, dyspnea symptoms, and health-related quality of life. However, no significant improvement was observed in forced expiratory volume in 1 second (FEV₁) percent predicted. Importantly, a subgroup analysis revealed that individuals with a baseline PaCO₂ of \geq 55 mm Hg had a greater mortality benefit (RR, 0.69; p = 0.02) than those with a PaCO₂ of < 55 mm Hg (RR, 0.87; p = 0.32). Similarly, individuals who achieved a greater reduction in PaCO₂ had a significantly lower mortality risk (RR, 0.42; p < 0.0001) than those with smaller reductions (RR, 0.91; p = 0.38). The study had limitations. First, variability in the definition of stable hypercapnia may have influenced results, although a subgroup analysis showed consistent findings and no significant heterogeneity in mortality outcomes, supporting their credibility. Second, differences in measurement tools and data types limited the pooling of some secondary outcomes, resulting in low-quality evidence. Third, the study quality varied, with many trials showing potential bias in selection, performance, and detection, which was considered in the evidence assessment. Lastly, while clinical trials suggest a link between PaCO₂ reduction and lower mortality, the underlying mechanisms remain unclear. The authors concluded that the initial PaCO₂ levels and their subsequent reduction may reflect the therapeutic impact of LTHNIPPV in individuals with stable hypercapnic COPD. To validate these findings, further large-scale, multicenter RCTs are warranted.

Wilson et al. (2020) conducted a comprehensive systematic review and meta-analysis to evaluate the impact of home noninvasive positive pressure ventilation (NIPPV) on clinical outcomes in individuals with COPD and hypercapnia. The PaCO₂ thresholds used to initiate NIPPV were associated with effect sizes for four primary outcomes: mortality, need for intubation, quality of life, and all-cause hospital admissions. The authors categorized PaCO₂ thresholds as 45 to 49 mm Hg, 50 to 51 mm Hg, and \geq 52 mm Hg. Analyzing data from 21 RCTs and 12 observational studies that involved over 51,000 individuals, the study found that bilevel positive airway pressure (BPAP) was significantly associated with reduced mortality [odds ratio (OR), 0.66], fewer hospital admissions (OR, 0.22), and a lower need for intubation (OR, 0.34) compared with no device use. However, no significant improvement in quality of life was observed. Noninvasive HMVs also reduced hospital admissions but did not significantly affect mortality. BPAP was associated with stronger clinical benefits, possibly due to its superior ability to support ventilation and reduce PaCO₂ levels. The overall quality of evidence

ranged from low to moderate, and many outcomes were based on a limited number of studies. These findings suggest that home NIPPV may improve survival and reduce healthcare utilization in individuals with hypercapnic COPD, although its effect on quality of life remains uncertain. Further high-quality research is needed to clarify these outcomes (Bhatt et al., included in this study).

Bhatt et al. (2013) conducted an RCT to investigate the effects of home NIPPV in participants with stable COPD who had a PaCO₂ level below 52 mm Hg, indicating normocapnia or mild hypercapnia. Overall, 30 participants with severe airflow limitation (FEV₁ < 50% predicted) were randomized to receive either NIPPV (BPAP at 15/5 cm H₂O) or usual care for 6 months. The study found that NIPPV led to modest improvements in dyspnea, particularly in Transitional Dyspnea Index scores at 6 weeks and 3 months, with sustained benefit in the Transitional Dyspnea Index-Task domain at 6 months. A small but statistically significant improvement in the Chronic Respiratory Questionnaire-Mastery domain of quality of life was observed. Importantly, while PaO₂ remained stable in the NIPPV group, it declined in the control group, suggesting a protective effect of NIPPV on oxygenation. The authors noted several strengths, including the focus on participants with stable COPD who were not significantly hypercapnic, which is an atypical target group for NIPPV. By excluding participants with sleep apnea, they aimed to isolate the effects of NIPPV on COPD-related outcomes and carefully monitored mask-related side effects. However, the study had limitations: it lacked a sham control arm, which may have introduced placebo effects; the control group consisted entirely of male participants, raising concerns about gender bias; and the study was underpowered to assess outcomes such as mortality and exacerbation rates. Additionally, participant adherence was low, likely due to the absence of pressure titration, a run-in period, and the nature of the intervention (issues common in similar studies). The study concluded that NIPPV may offer limited but meaningful benefits in quality of life and dyspnea for individuals with stable COPD with a PaCO₂ of < 52 mm Hg, warranting further research in this subgroup.

Noninvasive Airway Assistive Devices

Bilevel Positive Airway Pressure (BiPAP) Including Humidifiers

Due to insufficient evidence, BiPAP is considered unproven for individuals with COPD when arterial PaCO₂ is less than 52 mmHg while awake, on room air (even when the asleep PaCO₂ is at 55mmHg or more for at least ten minutes, or asleep PaCO₂ increase of > 10mmHg from baseline awake and > 50mmHg for at least ten minutes during sleep time).

In a Cochrane Review conducted by Pinto et al. (2022), the authors assessed the effectiveness and safety of NIPV for the treatment of adults with central sleep apnea. A search was conducted in the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, and Scopus. The search resulted in 15 RCTs which included 1,936 individuals. The authors found that continuous positive airway pressure (CPAP) plus best supportive care may reduce central Apnea Hypopnea Index (AHI) in individuals with CSA that is associated with chronic heart failure; however, it does not decrease the cardiovascular mortality. The available evidence is uncertain, and no definitive conclusions could be drawn; therefore, additional high-quality trials are warranted to determine whether NIPPV is better than another mode or better than best supportive care. Future studies should focus on individual-centered outcomes, quality of life, quality of sleep, and long-term survival.

In a multicenter RCT, Masa et al. (2019) sought to determine the long-term effectiveness of both CPAP and noninvasive ventilation (NIV) therapy treatment modalities in participants with obesity hypoventilation syndrome. There were two phases of the study, with an original 221 participants screened. The first phase was designed to assess the effect of the three separate groups (NIV, CPAP, and lifestyle changes) on daytime PaCO₂, quality of life, spirometry, 6-minute walk distance, and polysomnography. The second phase of the study randomized 204 participants to either the NIV or CPAP group; these participants were followed up for 3 years and instructed on lifestyle modification. In addition, supplemental oxygen therapy was added if baseline hypoxemia was identified. CPAP titration was done at the time of conventional polysomnography; the mean continuous positive pressure setting was 10.7 cm H₂O. The initial NIV adjustment was completed during wakefulness. The expiratory positive airway pressure (PAP) was set between 4 and 8 cm H₂O, and the inspiratory PAP was set between 18 and 22 cm H₂O. Participants were evaluated at baseline, at the first and second months, and every 3 months thereafter through 2 years and then every 6 months until completion of year 3. The authors concluded that NIV and CPAP appear to have similar long-term efficacy; however, CPAP may be the preferred first-line treatment. Thus, individual assessment is recommended.

Murphy et al. (2017) examined the effect of home NIV plus oxygen in participants with persistent hypercapnia after an acute exacerbation of COPD. Overall, 116 participants were randomized to either receive home oxygen therapy plus home NIV (n = 57) or home oxygen therapy alone (n = 59); between the two groups, 18 participants withdrew from the trial. NIV was initiated by using nasal, oronasal, or total face masks (per individual preference) and delivered using the Harmony 2 ventilator (Philips Respironics) or the VPAP III ST-A ventilator (ResMed). The goal was to achieve control of nocturnal hypoventilation with a high-pressure ventilation strategy. All participants were instructed to use oxygen therapy

for at least 15 hours/day, which was initiated at the lowest flow rate required to increase the PaO₂ level to greater than 60 mm Hg. The group using ventilation was also directed to use the ventilator for a minimum of 6 hours nightly. The primary outcome was time to readmission or death within 12 months following randomization. Secondary outcomes included exacerbation frequency, change in PaO₂ and PaCO₂, change in control of sleep-disordered breathing, and health-related quality of life. The results revealed that the median time to readmission or death was 4.3 months in the home oxygen therapy plus home NIV group vs 1.4 months in the home oxygen therapy alone group. There was not a significant difference between the two groups in 12-month mortality: 16 participants in the home oxygen therapy plus home NIV group vs 19 participants in the home oxygen therapy alone group. The authors concluded that the amount of time to readmission or death was prolonged when NIV was added to home oxygen therapy, which in turn supports the screening of individuals with COPD following acute intervention and presents home NIV as a valid option. Limitations include the concern over the effectiveness of blinding because both participants and clinicians were able to identify the sham intervention, limiting the scientific justification. Additionally, provisions were made for participants who were part of the home oxygen therapy alone group to add NIV after reaching the primary outcome.

In a meta-analysis of RCTs, Liao et al. (2017) studied the efficacy of long-term NIPPV in individuals with stable hypercapnic COPD with respiratory failure. A comprehensive search was conducted using PubMed, the Cochrane Library, Embase, Ovid, and the Chinese Biomedical Literature Database. Overall, 1,014 studies were found, and seven studies, with 810 individuals, were identified and used for analysis. Two studies were shown to be at low risk of bias, while five of the studies were unclear. The authors found that long-term NIPPV significantly decreased PaCO₂ in individuals with COPD with chronic type II respiratory failure, but no significant difference was found in mortality, frequency of acute exacerbation, PaO₂, lung function, respiratory muscle function, and exercise capacity. Limitations include the inability of blinding for NIPPV, inconsistency in the quality of trials, and differences in the types of data and evaluation methods.

Zhou et al. (2017) investigated the effects of home NIV in participants with stable COPD with chronic hypercapnic respiratory failure by using an NIV ventilator that was equipped with built-in software. Participants were recruited from 20 respiratory units; 115 participants who were ≥ 40 years of age and deemed clinical stable were included. Participants were randomly assigned to either the NIPPV group (n = 57) or control group (n = 58). All participants received long-term oxygen therapy via nasal cannula at a flow rate of 1 to 3 L/min to achieve oxygen saturation of 90%, and usage was at least 15 hours per day. In the NIPPV group, NIV was used on the home setting for at least 5 hours per day. The installed built-in software recorded the parameters. These parameters included the estimation of leaks, inspiratory PAP, expiratory PAP, tidal volume, minute ventilation, respiratory rate, backup frequency, and percentage of inspirations triggered by the participant. The primary end point was PaCO₂. Overall adherence to the NIV treatment went well and resulted in a mean time of NIV usage at 5.6 ± 1.4 hours per day. When the authors compared results with the baseline data, they found a decrease in PaCO₂ in the intervention group vs the control group (-10.41 ± 0.97 vs -4.32 ± 0.68 mm Hg; p = 0.03). The authors concluded that ventilators that were equipped with built-in software provided methodology for monitoring NIPPV use at home, which could in turn increase adherence of NIPPV use. The authors revealed that 3-month usage of NIPPV reduced PaCO₂ in participants with chronic hypercapnic COPD. Limitations include the lack of long-term outcomes.

Kuklisova et al. (2016) evaluated the effects of BPAP in individuals with obstructive sleep apnea (OSA) and concurrent COPD. The aim of the study was to analyze early predictors of CPAP failure in individuals and evaluate the effects of BPAP in this high-risk group of individuals. Overall, 84 individuals were included in the study; documentation reflected a mean AHI of 33.2, daytime capillary PO₂ of 9.0 kPa, and PCO₂ of 5.5 kPa. CPAP treatment, along with titration, followed American Academy of Sleep Medicine guidelines. Follow-up visits included individual interviews, along with questionnaire completion, equipment inspection and data retrieval, and individual weights. Primary CPAP failure was found in 23% of individuals who were obese, had worsening lung function, and had a lower PO₂ and higher PCO₂ while awake compared with those who responded to CPAP. When the authors compared the CPAP group with the BPAP group, individuals who required BPAP had a higher body mass index, lower FEV₁ and FEV₁/forced vital capacity, and worse gas exchange while awake, as evidenced by a lower capillary SpO₂, lower PO₂, and higher PCO₂. Limitations include the retrospective design of the study and performance of a capillary analysis instead of an arterial blood gas analysis.

Cowie et al. (2015) conducted the SERVE-HF trial, which investigated the effects of adding adaptive servo-ventilation (ASV) to guideline-based medical treatment in participants with CSA and heart failure. Overall, 1,325 participants with a left ventricular ejection fraction (LVEF) of 45% or less, AHI of 15 or more events per hour, and large number of central events were randomly assigned to one of two groups; group one participants received medical treatment with ASV, and group two participants received medical treatment alone (control). The primary outcomes that were analyzed were death, a lifesaving cardiovascular intervention (such as transplant), or an unplanned hospitalization for worsening chronic heart failure. Quality of life was assessed using the EuroQoL Group 5-Dimension Self-Report Questionnaire. Participants were instructed to use the ASV device for at least 5 hours per night, 7 days per week, and adherence was defined as an average of at least 3 hours per night. The goal was to reduce the AHI to less than 10 events per hour within 14 days after starting ASV. Participants were seen after 2 weeks, again at 3 and 12 months, and every year thereafter. Participants in

the ASV group underwent polysomnography at each visit, and data from the ASV device were downloaded. The authors found that although the group of participants that received ASV therapy effectively treated their CSA, it did not show any significant improvements over the guideline-based medical treatment. Limitations include the unblinded design, which may have introduced bias; lack of female participants; and inability to generalize results of findings because the participants who were selected had heart failure with reduced ejection fraction. Thus, the results could not be applied to those participants with a preserved ejection fraction.

A multicenter RCT investigated the effects of long-term NIPPV use in 195 participants with advanced stable hypercapnic COPD (Köhnlein et al., 2014). Participants were randomized into the NIPPV group (n = 102) or the control group (n = 93). Inclusion criteria consisted of participants aged 18 years or older with stable COPD who had a baseline PaCO₂ of 7 kPa or higher and a pH higher than 7.35. Exclusion criteria consisted of participants with a body mass index of ≥ 35 kg/m², previous initiation of NIPPV, malignant comorbidities, severe heart failure, unstable angina, and severe arrhythmias. The control group received optimized COPD therapy without NIPPV; the intervention group received optimized COPD therapy plus NIPPV. The intervention group was instructed to use NIPPV for at least 6 hours/day, preferably during sleep, but daytime usage was accepted. After the first visit on day 14, additional follow-up consisted of 3, 6, 9, and 12 months. NIPPV was targeted to reduce the baseline PaCO₂ by 20% or more or achieve PaCO₂ values lower than 6.5 kPa. The authors found that adding long-term use of NIPPV to standard treatment improved survival in participants with hypercapnic stable COPD. The control group had a 1-year mortality of 33%, but this was only 12% in the intervention group. Limitations include recruitment difficulties, the lack of masking, the lack of long-term outcomes, and a sample size that was not as large as intended.

Blau et al. (2012) conducted a prospective, double-blinded, randomized trial to evaluate the efficacy of and adherence to CPAP against Auto Bi-Level Pressure Relief-Positive Airway Pressure (ABPR-PAP) in participants with OSA. Overall, 35 participants who were diagnosed with moderate to severe OSA were randomized into either the CPAP group (n = 18) or the ABPR-PAP group (n = 17). The same device (BiPAP® Auto with Bi-Flex®; Philips Respironics) was used for both groups, and AHI was the primary outcome, determined by polysomnography before and after treatment. Assessment of adherence was measured at 2 and 12 weeks with the machine's Encore Pro® Smartcard. The authors found that after 3 months of use, the AHI decreased in the CPAP group to 4.4 \pm 5.3 per hour and in the ABPR-PAP group to 2.6 \pm 3.8 per hour; differences between the groups were not statistically significant, and an adherence rate of 94% was achieved. While further research is required to determine which set of participants would benefit most from this therapy, the authors concluded that ABPR-PAP is promising and may provide an effective treatment for individuals with OSA. Limitations include the small sample size, the lack of long-term follow-up, and a participant population that was already familiar with CPAP use.

Powell et al. (2012) conducted an RCT, with 48 participants, to see if early intervention with an alternative device (autotitrating, bilevel, and pressure flexing) would improve therapy outcomes compared with standard CPAP in participants with OSA with a poor initial CPAP experience. Inclusion criteria consisted of participants who had a confirmed diagnosis of OSA, baseline AHI of ≥ 15 /hour, and suboptimal facility-based attended CPAP titration, according to standard clinical protocol, with ≥ 3 hours of attempted titration data. Participants with previous CPAP or bilevel use were excluded. Following randomization, participants underwent polysomnogram titration and then received their device, with usage instructions for the next 90 days. Education and counseling occurred, along with follow-up at 30 and 90 days; adherence was monitored via the device's tracking capabilities and downloaded after 1 week and 30 and 90 days. The Epworth Sleepiness Scale and Fatigue Severity Scale were used to assess subjective estimates of sleepiness and fatigue, along with the Functional Outcomes of Sleep Questionnaire. The authors found no significant difference between the two groups related to adherence; therefore, it seemed that the auto bilevel device was just as effective as CPAP therapy. Limitations include a pilot study with a small sample size; therefore, it was not powered to assess significant differences between the two groups. Additionally, the study lacked long-term outcomes.

Ballard et al. (2007) studied 204 participants with previously diagnosed OSA and nonadherence with CPAP. There were two phases of the study. Phase 1 evaluated standard interventions to improve therapy adherence, including mask optimization, heated humidification, topical nasal therapy, and sleep apnea education. Participants who were consistently nonadherent were moved into phase 2 of the study; participants were randomized into two groups that assessed adherence between standard CPAP vs flexible bilevel positive airway pressure (BiFlex). Of the original 204 nonadherent participants, 49% became adherent and had an average nightly use of > 4 hours. Of the 155 left, 104 agreed to continue to the second phase; 53 participants were randomized to CPAP, and 51 were randomized to BiFlex therapy. The authors found that 25 BiFlex participants were adherent to therapy after ≥ 90 days of treatment, as opposed to only 15 of the CPAP participants. Following review of the data, the authors concluded that a change to flexible bilevel airway pressure can achieve improved adherence in individuals who were previously nonadherent with CPAP.

Respiratory Assist Device, Bilevel Pressure Capability, With Backup Rate Feature

Due to insufficient evidence, BPAP (with or without backup rate) is considered unproven for individuals with CSA or OSA when adherent use of BPAP is less than 4 hours during sleep time in at least 21 to 30 consecutive 24-hour periods.

In a Cochrane Review that was conducted by Askland et al. (2020), the authors assessed the effectiveness of educational, supportive, and/or behavioral therapies in adults who have been diagnosed with OSA and prescribed CPAP. It was theorized that educational, supportive, and behavioral interventions may help initiate and maintain regular and continued use of CPAP. A comprehensive literature search was conducted and returned 41 studies (randomized, parallel group, and controlled). The trials included just over 9,000 individuals and were grouped into the following: (1) education, (2) a supportive intervention, (3) behavioral intervention, and (4) a mixed intervention that used all three techniques. Due to the uncertainty of the evidence, the authors were unable to determine whether educational interventions improved device usage or not, but there was a high level of confidence that behavioral interventions showed a clinically significant increase in hourly usage of the device compared with usual care. In addition, there was moderate certainty of evidence that demonstrated that supportive interventions had a positive effect.

In a Cochrane Review that was conducted by Yamamoto et al. (2019), assessment was conducted on the effects of PAP therapy for people with heart failure who experience CSA. A search was conducted using the Cochrane Library, MEDLINE, Embase, and the Web of Science Core Collection. Sixteen RCTs, involving a total of 2,125 individuals, were included for review. The trials included individuals with heart failure and a reduced ejection fraction, along with PAP therapy that consisted of ASV or continuous PAP therapy for 1 to 31 months. The authors found that the effects of PAP therapy were uncertain. While evidence was found to show that PAP therapy did not reduce the risk of cardiac-related mortality and rehospitalization, there was some indication that it may provide improvement in quality of life in individuals with heart failure and CSA. While these findings were limited by low- or very-low-quality evidence, PAP therapy may be worth considering for individuals with heart failure to improve their quality of life.

Pépin et al. (2018) investigated adherence rates in individuals with sleep apnea based on the type of PAP device used and the switching of PAP modality over time. The study included 198,890 individuals, who were divided into three distinct groups: CPAP only (started on CPAP and stayed on CPAP, n = 189,724); ASV only (started on ASV and stayed on ASV, n = 8,957); and switch (started on CPAP, switched to ASV, n = 209). Adherence was defined as device usage for ≥ 4 hours per night on 70% of nights during a consecutive 30-day period any time during the first 3 months of initial use. The average usage per day was calculated by dividing the total number of hours used in the period by the number of days in the period, where the period was defined as day 1 to day 30, day 60, or day 90 or to the end date of the specific therapy. Results that were identified in the switch group showed that AHI decreased significantly with ASV vs CPAP use. At 90 days, adherence rates were 73.8% and 73.2% in the CPAP-only and ASV-only groups. In the switch group, CPAP adherence was 62.7%, improving to 76.6% after the switch to ASV. The mean device usage at 90 days was 5.27, 5.31, and 5.73 hours/day in the CPAP-only, ASV-only, and switch groups, respectively. The authors concluded that treatment-emergent or persistent CSA during CPAP reduced therapy adherence, but adherence improved after switching from CPAP to ASV. Limitations include the lack of demographic data, lack of comorbid conditions, and lack of information on the specific rationale from clinicians when switching individuals from CPAP to ASV. Further studies, including RCTs, are needed to assess the effect of ASV in individuals with persistent or treatment-emergent CSA during CPAP.

Arzt et al. (2013) performed a multicenter, randomized, open-label, parallel-group trial to assess whether ASV improves daytime cardiac function in participants with heart failure and sleep-disordered breathing as well as quality of life compared with stable optimal medical management alone. Inclusion criteria consisted of participants aged 18 to 80 years of age who had congestive heart failure (New York Heart Association class II-III) with an LVEF of $\leq 40\%$; stable optimal medical therapy for at least 4 weeks; and an AHI of ≥ 20 events per hour, as assessed by polysomnography. Overall, 72 participants were randomly assigned to either the control group (optimal medical management for heart failure) or the ASV group (ASV therapy in addition to optimal medical management). For the ASV group, the expiratory PAP of the ASV device was set to the determined night CPAP titration. The minimum and maximum pressures were set, and the default backup rate of the machine was used. The information was obtained and saved onto a smart card located in the device. The primary outcome of the trial was the change in LVEF within 12 weeks of treatment. The ASV device was used daily for approximately 4.5 hours, with a mean expiratory PAP of 8.1 ± 1.7 cm H₂O and a maximum inspiratory PAP of 14.0 ± 5.3 cm H₂O; the automatic backup rate was used in all participants. The authors found that the change in LVEF was similar in both the ASV and control groups and showed a modest improvement. In subanalyses in participants with OSA (n = 36) and CSA (n = 32), the change in LVEF was not significantly different between the ASV and control groups. For secondary outcomes, AHI and central AHI were decreased in the ASV group compared with the control group. It was concluded that the trial supported that ASV was an effective treatment for both participants with CSA and OSA. Limitations include the small sample size, changes in diuretic treatment for participants with worsening symptoms during the trial, and a per-protocol analysis that did not comply with the calculated sample size.

Dellweg et al. (2013) compared NIPPV and anticyclic servo-ventilation in 30 participants who developed complex sleep apnea syndrome during CPAP treatment. Participants were randomized into one of two groups: (1) standard NIPPV ventilator or (2) dynamic servo-ventilation. After titration to the respective device, participants were told to use their device nightly during sleep and could contact the sleep center for any problems; however, participants were not actively contacted by the facility during the treatment period of 6 weeks. Adherence was recorded from the machines. The authors found that NIPPV and servo-ventilation were able to suppress central and obstructive events during initial titration, but after 6 weeks, servo-ventilation was shown to be superior to NIPPV. Limitations include the small sample size, lack of blinding, and occurrence of potential manual titration by the participant.

Chowdhuri et al. (2012) conducted a retrospective review over 3 years on the management of CSA associated with varying comorbidities and opioid use in patients and reported the effectiveness of titration with PAP (used alone or in conjunction with oxygen). Three groups of patients were studied: CPAP only, CPAP plus O₂, and BPAP plus O₂. The CSA treatment protocol consisted of positive pressure titration that was initiated at CPAP of 4 to 5 cm H₂O and titrated upward to 10 to 14 cm H₂O. If frequent central apneas persisted at the designated CPAP pressures of 10 to 14 cm H₂O, then no further increase of CPAP occurred; instead, oxygen was introduced. If central apneas persisted despite the addition of supplemental O₂, CPAP was switched to BPAP while maintaining an oxygen saturation of ≥ 93%. There was an optimal response in 127 of the 151 patients following the protocol; in addition, the most effective common therapeutic modality was CPAP, which occurred in 48% of the patients. Reduction in the AHI and Central Apnea Index was achieved in each group. In 12 patients, the addition of oxygen did not eliminate central apnea adequately (Central Apnea Index > 5/hour), despite attaining adequate oxygen saturation. The authors concluded that (1) CPAP therapy was effective in 50% of the population that was studied; (2) supplemental oxygen therapy with PAP was effective in an additional 35% of cases; (3) narcotic use was very common in patients with CSA and a more common risk factor for CSA than heart failure; and (4) PAP with added oxygen therapy was effective in patients with CSA and opioid drug use and may be considered as alternative therapy when central apneas are not eliminated by CPAP alone. Limitations include the design of the study; use of the BPAP spontaneous mode without a backup rate; lack of rapid-eye-movement sleep, which, if induced, might have eliminated some of the central events; and inability to confirm the amounts of opioids ingested.

Clinical Practice Guidelines

American Academy of Sleep Medicine (AASM)

The American Academy of Sleep Medicine commissioned a task force of board-certified sleep medicine specialists and experts with proficiency in the use of PAP in adults with OSA to develop recommendations based on a systematic review of the literature (Patil et al., 2019). The AASM board of directors made the following recommendations:

- Recommend that clinicians use PAP, compared with no therapy, to treat OSA in adults with excessive sleepiness. (STRONG)
- Suggest that clinicians use PAP, compared with no therapy, to treat OSA in adults with impaired sleep-related quality of life. (CONDITIONAL)
- Suggest that clinicians use PAP, compared with no therapy, to treat OSA in adults with comorbid hypertension. (CONDITIONAL)
- Recommend that PAP therapy be initiated using either auto-adjusted positive airway pressure (APAP) at home or in-laboratory PAP titration in adults with OSA and no significant comorbidities. (STRONG)
- Recommend that clinicians use either CPAP or APAP for ongoing treatment of OSA in adults. (STRONG)
- Suggest that clinicians use CPAP or APAP over BPAP in the routine treatment of OSA in adults. (CONDITIONAL)
- Recommend that educational interventions be given with initiation of PAP therapy in adults with OSA. (STRONG)
- Suggest that behavioral and/or troubleshooting interventions be given during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)
- Suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)

American College of Chest Physicians (CHEST)

In August 2025, CHEST published a new fact sheet for NIV in the home for the treatment of COPD based on a new coverage document by the Centers for Medicare and Medicaid Services. The new criteria for coverage of NIPPV in the treatment of chronic respiratory failure consequent to COPD are as follows:

- Removal of the prior requirement to perform overnight oximetry to document nocturnal hypoxemia
- Patients with COPD are eligible:
 - If they have hypercapnia of PaCO₂ 52 mm Hg (based on arterial blood gas); or
 - If sleep apnea is not the predominant cause of hypercapnia (based on documentation); or
 - If either stable COPD or hypercapnia is present at least 2 weeks following their hospitalization after resolution of a COPD exacerbation

- Evaluation within 6 months of starting NIPPV and must show:
 - Normalization of PaCO₂; or
 - Stabilization of rising PaCO₂; or
 - 20% reduction in PaCO₂ from baseline; or
 - Improvement in symptoms associated with chronic hypercapnia
- An HMV is indicated if the patient:
 - Requires O₂ therapy of FiO₂ of 36% or 4L nasally
 - Requires ventilatory support for more than 8 hours/day; or
 - Requires the alarms or internal battery of an HMV
- Continued use of either a BPAP device or HMV requires usage of at least 4 hours/day on at least 70% of days each month

American Thoracic Society (ATS)

For patients with chronic hypercapnic respiratory failure due to COPD, the ATS makes the following recommendations in a clinical practice guideline on long-term NIV (Macrea et al., 2020):

- Suggest the use of nocturnal NIV, in addition to usual care for patients with chronic stable hypercapnic COPD (conditional recommendation, moderate certainty).
- Suggest that patients with chronic stable hypercapnic COPD undergo screening for OSA before initiation of long-term NIV (conditional recommendation, very low certainty).
- Suggest not initiating long-term NIV during an admission for acute-on-chronic hypercapnic respiratory failure, favoring instead reassessment for NIV at 2 to 4 weeks after resolution (conditional recommendation, low certainty).
- Suggest not using an in-laboratory overnight polysomnogram to titrate NIV in patients with chronic stable hypercapnic COPD who are initiating NIV (conditional recommendation, very low certainty).
- Suggest NIV with targeted normalization of PaCO₂ in patients with hypercapnic COPD on long-term NIV (conditional recommendation, low certainty).

After considering the overall very low quality of the evidence, the ATS states that CPAP, rather than NIV, should be offered as the first-line treatment for stable, ambulatory patients with obesity hypoventilation syndrome and coexistent severe OSA (Mokhlesi et al., 2019).

Canadian Thoracic Society

This 2021 practice guideline provides updated recommendations on long-term NIV for patients with severe COPD and chronic hypercapnic respiratory failure (FEV₁ < 50% predicted). It focuses on two groups: (1) stable patients with severe COPD and hypercapnia and (2) those with persistent hypercapnia following an acute exacerbation requiring NIV. The guideline was developed by a multidisciplinary panel and based on English-language RCTs that were published between June 2010 and November 2020. Studies that involved sleep apnea or obesity-related hypoventilation were excluded. Risk of bias was assessed using the Cochrane tool, and evidence certainty was rated using Grading of Recommendations Assessment, Development, and Evaluation.

- In patients with stable, severe COPD and chronic hypercapnic respiratory failure (PaCO₂ ≥ 52 mm Hg), it was suggested that long-term NIV be used to improve survival [strength of evidence (SOE): weak/conditional; low certainty].
- In patients with severe COPD on long-term oxygen therapy who remain significantly hypercapnic (persistent PaCO₂ ≥ 52 mm Hg) at least 2 weeks after discontinuing NIV for an acute exacerbation, it was suggested that long-term NIV be used to delay hospital readmission (SOE: weak/conditional; very low certainty).
- When applying long-term NIV to patients with COPD and chronic hypercapnic respiratory failure (persistent PaCO₂ ≥ 52 mm Hg), it was suggested that high-intensity NIV instead of low-intensity NIV be used to improve PaCO₂ (SOE: weak/conditional; low certainty).
- The guidelines did not recommend the use of volume-assured pressure-preset NIV over standard pressure-preset NIV in patients with COPD and chronic hypercapnic respiratory failure (SOE: strong; low certainty).

This guideline marked a significant shift from its 2011 stance and now offers a favorable (although weak/conditional) recommendation for long-term NIV in select patients with COPD with chronic hypercapnic respiratory failure. It emphasizes aligning therapy with patient preferences, especially when NIV is used for more than 5 hours daily, effectively reduces PaCO₂, and controls nocturnal hypoventilation. Further research is encouraged (Kaminska et al., 2021).

Department of Veterans Affairs (VA)/Department of Defense (DOD)

The 2025 guideline for the management of chronic insomnia disorder and OSA makes the following recommendations for the treatment and management of OSA:

The following recommendations may help with adherence to PAP usage:

- Provide education regarding OSA and the prescribed treatment modality
- Use of heated humidification
- Ensure appropriate mask choice
- Cognitive behavior therapies to modify distorted view of OSA, enhance adherence through the development of positive associations with PAP, and integrate structured social support mechanisms
- Investigate and address high leakage issues
- On initial implementation of PAP, follow up at 4 weeks or earlier to evaluate usage

National Institute for Health and Care Excellence (NICE)

NICE (2021) recommends the following treatments for moderate and severe obstructive sleep apnea/hypopnea syndrome (OSAHS):

- CPAP is recommended as a treatment option for adults with moderate or severe symptomatic OSAHS.
- Offer fixed-level CPAP, in addition to lifestyle advice, to people with moderate or severe OSAHS.
- Consider auto-CPAP as an alternative to fixed-level CPAP in people with moderate or severe OSAHS if they are unable to tolerate fixed-level CPAP.

NICE (2021) recommends the following on CPAP and NIV for people with COPD-OSAHS overlap syndrome:

- Consider CPAP as first-line treatment for people with COPD-OSAHS overlap syndrome if they do not have severe hypercapnia (PaCO₂ of 7.0 kPa or less).
- Consider NIV instead of CPAP for people with COPD-OSAHS overlap syndrome with nocturnal hypoventilation if they have severe hypercapnia (PaCO₂ greater than 7.0 kPa).
- Offer face-to-face initial consultation within 1 month and subsequent follow-up, according to the person's needs and until optimal control of symptoms, AHI, Oxygen Desaturation Index, and oxygenation and hypercapnia is achieved.
- When NIV or CPAP (with or without oxygen therapy) has been optimized for people with COPD-OSAHS overlap syndrome, consider follow-up every 6 months to annually, according to the person's needs.

NICE (2018; updated 2019) recommends the following for NIV and COPD exacerbations:

- Use NIV as the treatment of choice for persistent hypercapnic ventilatory failure during exacerbations despite optimal medical therapy.
- Recommend that NIV be delivered in a dedicated setting, with staff that have been trained in its application, are experienced in its use, and are aware of the limitations.
- When someone is started on NIV, there should be a clear plan for what to do in the event of deterioration, and the maximum level of intervention should be agreed in advance.

Swiss Society of Pulmonology

The Special Interest Group of the Swiss Society of Pulmonology issued conditional recommendations for initiating long-term NIV in patients with COPD. The Special Interest Group suggests the following recommendations (Janssens et al., 2020).

- Long-term NIV should be used in chronic, stable hypercapnic patients [PaCO₂ > 7 kPa (52.5 mm Hg)] with severe COPD.
- Long-term NIV should be implemented after an acute episode of hypercapnic respiratory failure only if hypercapnia [PaCO₂ > 7 kPa (52.5 mm Hg)] persists 2 to 4 weeks after the acute episode.
- The potential benefit of long-term NIV for a recurrent acute episode of hypercapnic respiratory failure without persistent hypercapnia at 2 to 4 weeks remains undetermined.
- When implementing NIV in patients with COPD with chronic hypercapnic respiratory failure, settings should be adjusted to decrease PaCO₂ below 6.5 kPa (50 mm Hg) or reduce PaCO₂ levels by more than 20% of the baseline level.
- When implementing NIV in patients with COPD with chronic hypercapnic respiratory failure, fixed-pressure support ventilation should be preferred to autotitrating modes as the first-choice mode.

References

American College of Chest Physicians. New coverage guidelines for noninvasive ventilation in the home for the treatment of COPD. Glenview (IL): CHEST; 2025 [20250820]. Available at: <https://www.chestnet.org/newsroom/chest-news/2025/07/fact-sheet-new-coverage-guidelines-for-noninvasive-ventilation-in-the-home-for-the-treatment-of-copd>. Accessed September 25, 2025.

Arzt M, Schroll S, Series F, et al. Auto-servoventilation in heart failure with sleep apnoea: a randomised controlled trial. *Eur Respir J*. 2013 Nov;42(5):1244-54.

Askland K, Wright L, Wozniak DR, et al. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. *Cochrane Database Syst Rev*. 2020 Apr 7;4(4):CD007736.

Ballard RD, Gay PC, Strollo PJ. Interventions to improve compliance in sleep apnea patients previously non-compliant with continuous positive airway pressure. *J Clin Sleep Med*. 2007 Dec 15;3(7):706-12.

Bhatt SP, Peterson MW, Wilson JS, et al. Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. *Int J Chron Obstruct Pulmon Dis*. 2013;8:581-9.

Blau A, Minx M, Peter JG, et al. Auto bi-level pressure relief-PAP is as effective as CPAP in OSA patients--a pilot study. *Sleep Breath*. 2012 Sep;16(3):773-9.

Centers for Disease Control and Prevention. https://www.cdc.gov/growthcharts/clinical_charts.htm. Accessed October 2, 2025.

Centers for Medicare and Medicaid Services (CMS). Medicare Benefit Policy Manual, Chapter 15 – Covered Medical and Other Health Service. August 2021. Available at: https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/bp102c15_0.pdf. Accessed October 2, 2025.

Centers for Medicare and Medicaid Services (CMS). New Healthcare Common Procedure Coding System (HCPCS) Codes for Customized Durable Medical Equipment. July 2013. Available at: <https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/MM8158.pdf>. Accessed October 2, 2025.

Chowdhuri S, Ghabsha A, Sinha P, et al. Treatment of central sleep apnea in U.S. veterans. *J Clin Sleep Med*. 2012 Oct 15;8(5):555-63.

Code of Federal Regulations (CFR). Home health services. 42 CFR 440.70. Available at: <https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-440/subpart-A/section-440.70>. Accessed September 25, 2024.

Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. *n Engl J Med*. 2015 Sep 17;373(12):1095-105.

Dellweg D, Kerl J, Hoehn E, et al. Randomized controlled trial of noninvasive positive pressure ventilation (NPPV) versus servoventilation in patients with CPAP-induced central sleep apnea (complex sleep apnea). *Sleep*. 2013 Aug 1;36(8):1163-71.

Department of Veterans Affairs and the Department of Defense Clinical Practice Guideline for the management of chronic insomnia disorder and obstructive sleep apnea. Version 3.0. October 2025.

Ekkernkamp E, Kabitz HJ, Walker DJ, et al. Minute ventilation during spontaneous breathing, high-intensity noninvasive positive pressure ventilation and intelligent volume assured pressure support in hypercapnic COPD. *COPD*. 2014 Feb;11(1):52-8.

Janssens JP, Michel F, Scwarz E, et al., on behalf of the Special Interest Group on Ventilation and Oxygen Therapy of the Swiss Society of Pneumology. Long-Term Mechanical Ventilation: Recommendations of the Swiss Society of Pulmonology. *Respiration*. 2020 Dec 10:1-36. doi: 10.1159/000510086. Epub ahead of print. PMID: 33302274.

Kaminska M, Rimmer KP, McKim DA, et al. Long-term non-invasive ventilation in patients with chronic obstructive pulmonary disease (COPD): 2021 Canadian Thoracic Society Clinical Practice Guideline update. *Can J Respir Crit Care Sleep Med*. 2021;5(2):71–92.

Kentucky Administrative Regulations (KAR), Title 907, Chapter 001, Regulation 479: Medical supplies, equipment, and appliances covered benefits and reimbursement. <https://apps.legislature.ky.gov/Law/KAR/titles/907/001/479/index.html>. Accessed December 11, 2025.

Kentucky Administrative Regulations (KAR), Title 907, Chapter 001, Regulation 632: Vision Program coverage provisions and requirements. <https://apps.legislature.ky.gov/law/kar/907/001/632.pdf>. Accessed December 11, 2025.

Köhnlein T, Windisch W, Köhler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. *Lancet Respir Med*. 2014 Sep;2(9):698-705.

Kuklisova Z, Tkacova R, Joppa P, et al. Severity of nocturnal hypoxia and daytime hypercapnia predicts CPAP failure in patients with COPD and obstructive sleep apnea overlap syndrome. *Sleep Med*. 2017 Feb;30:139-145.

Liao H, Pei W, Li H, et al. Efficacy of long-term noninvasive positive pressure ventilation in stable hypercapnic COPD patients with respiratory failure: a meta-analysis of randomized controlled trials. *Int J Chron Obstruct Pulmon Dis*. 2017 Oct 10;12:2977-2985.

Macrea M, Oczkowski S, Rochweg B, et al. Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020 Aug 15;202(4):e74-e87.

Masa JF, Mokhlesi B, Benítez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. *Lancet*. 2019 Apr 27;393(10182):1721-1732.

Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2019 Aug 1;200(3):e6-e24.

Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. *JAMA*. 2017 Jun 6;317(21):2177-2186.

National Institute for Health and Care Excellence (NICE). NG115. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. July 2018.

National Institute for Health and Care Excellence (NICE). NG202. Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s. August 2021.

Noninvasive Respiratory Support | American Academy of Pediatrics (aappublications.org). Accessed October 2, 2025.

Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med*. 2019 Feb 15;15(2):301-334.

Pépin JL, Woehrle H, Liu D, et al. Adherence to positive airway therapy after switching from CPAP to ASV: a big data analysis. *J Clin Sleep Med*. 2018 Jan 15;14(1):57-63.

Pinto ACPN, Rocha A, Pachito DV, et al. Non-invasive positive pressure ventilation for central sleep apnoea in adults. *Cochrane Database Syst Rev*. 2022 Oct 24;10(10):CD012889.

Powell ED, Gay PC, Ojile JM, et al. A pilot study assessing adherence to auto-bilevel following a poor initial encounter with CPAP. *J Clin Sleep Med*. 2012 Feb 15;8(1):43-7.

Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: A systematic review and meta-analysis. *JAMA*. 2020 Feb 4;323(5):455-465.

Wu Z, Luo Z, Luo Z, et al. Baseline level and reduction in PaCO₂ are associated with the treatment effect of long-term home noninvasive positive pressure ventilation in stable hypercapnic patients with COPD: A systematic review and meta-analysis of randomized controlled trials. *Int J Chron Obstruct Pulmon Dis*. 2022 Apr 6;17:719-733.

Yamamoto S, Yamaga T, Nishie K, et al. Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure. *Cochrane Database Syst Rev*. 2019 Dec 4;12(12):CD012803.

Zhou L, Li X, Guan L, et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. *Int J Chron Obstruct Pulmon Dis*. 2017 Apr 27;12:1279-1286.

Policy History/Revision Information

Date	Summary of Changes
05/01/2026	<p>Coverage Rationale</p> <ul style="list-style-type: none"> • Added language to indicate this policy does not apply to Durable Medical Equipment or supplies used in an outpatient or inpatient facility • Revised list of clinical guidelines to be applied when determining medical necessity: <ul style="list-style-type: none"> ○ Added reference to the InterQual® Medicare: Post Acute & Durable Medical Equipment ○ Removed reference to the InterQual® Medicare: Post Acute & Durable Medical Equipment, Ventilators NCD <p>Home Mechanical Ventilators and Respiratory Assist Devices (Applies for 2 Years of Age or Older)</p> <ul style="list-style-type: none"> • Revised language pertaining to medical necessity clinical coverage criteria:

Date	Summary of Changes
	<ul style="list-style-type: none"> ○ Added reference to the InterQual® Client Defined, CP: Durable Medical Equipment Home Mechanical Ventilation Devices: Invasive, Noninvasive, and Multifunction (Custom) – UHG ○ Removed reference to the InterQual® Medicare: Post Acute & Durable Medical Equipment, Ventilators NCD ● Added language to indicate home mechanical ventilators are not medically necessary for individuals with stable COPD with an arterial PaCO₂ of less than 52 mm Hg while awake on room air ● Replaced language indicating: <ul style="list-style-type: none"> ○ “A bilevel PAP <i>device</i>, with or without backup rate, is considered unproven and not medically necessary due to insufficient <i>high-quality</i> evidence of safety and efficacy for individuals with central sleep apnea (CSA) and obstructive sleep apnea (OSA) when adherent use of bilevel PAP is for less than 4 hours during sleep time on at least 21 to 30 consecutive 24-hour periods” with “bilevel PAP, with or without backup rate, is considered unproven and not medically necessary due to insufficient evidence of safety and efficacy for individuals with central sleep apnea and obstructive sleep apnea when adherent use of bilevel PAP is for less than 4 hours during sleep time on at least 21 to 30 consecutive 24-hour periods” ○ “BiPAP is <i>considered</i> unproven and not medically necessary due to insufficient <i>high-quality</i> evidence of safety and efficacy for <i>patients</i> with chronic obstructive pulmonary disease (COPD) <i>when an</i> arterial PaCO₂ <i>is</i> less than 52 mm Hg while awake, even when the asleep PaCO₂ is at 55 mmHg or more for at least 10 minutes, or asleep PaCO₂ increase of > 10 mmHg from baseline awake and > 50 mmHg for at least 10 minutes during sleep time” with “bilevel PAP is unproven and not medically necessary due to insufficient evidence of safety and efficacy for <i>individuals</i> with chronic obstructive pulmonary disease (COPD), <i>with an</i> arterial PaCO₂ <i>of</i> less than 52 mm Hg while awake <i>on room air</i> (even when the asleep PaCO₂ is at 55 mm Hg or more for at least 10 minutes or asleep PaCO₂ increase of > 10 mm Hg from baseline awake and > 50 mm Hg for at least 10 minutes during sleep time)” <p>Dedicated Speech Generating Devices and Tracheo-Esophageal Voice Devices</p> <ul style="list-style-type: none"> ● Added instruction to refer to the <i>Kentucky Administrative Regulations (KAR); Title 907, Chapter 001, Regulation 479: Durable medical equipment covered benefits and reimbursement for medical necessity clinical coverage criteria</i> <p>Medical Records Documentation Used for Reviews</p> <ul style="list-style-type: none"> ● Added language to indicate: <ul style="list-style-type: none"> ○ Benefit coverage for health services is determined by the federal, state, or contractual requirements, and applicable laws that may require coverage for a specific service ○ Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the service requested ○ The patient's medical record must contain documentation that fully supports the medical necessity for the requested services ○ This documentation includes but is not limited to relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures ○ Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request <p>Benefit Considerations</p> <ul style="list-style-type: none"> ● Removed language indicating tracheo-esophageal prosthetics and voice aid prosthetics are covered as Durable Medical Equipment <p>Supporting Information</p> <ul style="list-style-type: none"> ● Updated <i>Clinical Evidence</i> and <i>References</i> sections to reflect the most current information ● Archived previous policy version CS032KY.07

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state, or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state, or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state, or contractual requirements for benefit plan coverage govern. Before using this policy, check the federal, state, or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its

Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare uses InterQual® for the primary medical/surgical criteria, and the American Society of Addiction Medicine (ASAM) for substance use, in administering health benefits. If InterQual® does not have applicable criteria, UnitedHealthcare may also use UnitedHealthcare Medical Policies, Coverage Determination Guidelines, and/or Utilization Review Guidelines that have been approved by the Kentucky Department for Medicaid Services. The UnitedHealthcare Medical Policies, Coverage Determination Guidelines, and Utilization Review Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.